Ali Saberi Shahrbabaki

Ali Saberi Shahrbabaki

Auto-generated profile, based on publicly available information

Ali Saberi Shahrbabaki

School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
TAToktam Alirezaei
Toktam Alirezaei
ZMZahra Mahboubi‐Fooladi
Zahra Mahboubi‐Fooladi
RIRana Irilouzadian
Rana Irilouzadian
ASAli Saberi Shahrbabaki
Ali Saberi Shahrbabaki
HGHaniyeh Golestani
Haniyeh Golestani
Background: Accurate risk stratification is the most important step in the management of patients with acute pulmonary thromboembolism (PTE). Pulmonary embolism severity index (PESI) is a clinical tool for PTE risk stratification. CHA2DS2‐VASc score, a risk assessment tool in patients with atrial fibrillation, is recently considered for acute PTE. The presence of right ventricular (RV) dysfunction in imaging is more efficient in acute PTE risk evaluation.Hypothesis: This study aims to evaluate the association between CHA2DS2‐VASc and PESI score and each of them with RV dysfunction on computed tomography pulmonary angiography (CTPA).Methods: One hundred eighteen patients with a definite diagnosis of PTE were entered. The CHA2DS2‐VASc and PESI scores were calculated for all of them. RV dysfunction including an increase in RV to left ventricular diameter ratio, interventricular septal bowing, and reflux of contrast medium into the inferior vena cava was examined by CTPA.Results: PESI and CHA2DS2‐VASc scores were significantly associated with RV dysfunction. In addition, different classes of PESI scores were correlated with RV dysfunction. Moreover, this study showed that the CHA2DS2‐VASc score and PESI score had a positive correlation. The area under the curve value for the CHA2DS2‐VASc score was 0.625 with 61.54% sensitivity and 60.0% specificity for predicting RV dysfunction while for PESI score was 0.635 with 66.7% sensitivity and 60.0% specificity.Conclusion: This study showed that not only CHA2DS2‐VASc and PESI scores are positively correlated, but they are both associated with RV dysfunction diagnosed by CTPA. CHA2DS2‐VASc and PESI scores are able to predict RV dysfunction.

25 December 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
ATAisa Talebi
Aisa Talebi
SDSam Zeraatian Nejad Davani
Sam Zeraatian Nejad Davani
ASAli Saberi Shahrbabaki
Ali Saberi Shahrbabaki
MMMilad Gholizadeh Mesgarha
Milad Gholizadeh Mesgarha
AMArash Pour Mohammad
Arash Pour Mohammad
AZAli Zare‐Mirzaie
Ali Zare‐Mirzaie

28 August 2025 in Natural Product Communications
Verified
Journal Article
Open access
ASAli Saberi Shahrbabaki
Ali Saberi Shahrbabaki
BABehnam Amini
Behnam Amini
MGMojtaba Ghorbani
Mojtaba Ghorbani
MGMoein Ghasemi
Moein Ghasemi
SGSara Ganjizadeh
Sara Ganjizadeh
MDMohammad R Delnavazi
Mohammad R Delnavazi
Background: Wound healing progresses through phases of homeostasis, inflammation, proliferation, and remodeling, regulated by signaling pathways. The root extract of Onosma microcarpum (OM), traditionally used in Western Iran for wound care, contains bioactive compounds like alkannin, shikonin, and polyphenols, potentially enhancing healing. This study evaluates OM's effects on wound healing through the signaling pathways in each phase. Methods: Dried OM root was formulated into ointments, and male Wistar rats with excisional wounds were treated with OM (0.2% or 1%) or vehicle. Wound closure rate, histological and gene expression analyses were conducted on days 3, 8, and 14, measuring inflammation, granulation, angiogenesis, and collagen formation. The mRNA expression of cytokines (Interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α)), growth factors (Transforming Growth Factor-β1 (TGF-β1), platelet-derived growth factor (PDGF)), and cell regulators (extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinases (JNK), p38 mitogen-activated protein kinase (p38 MAPK)) were analyzed. Results: OM at 0.2%, significantly modulated key pathways in wound healing. By day 3, OM reduced TNF-α ( P = 0.003) and IL-1β ( P = 0.008), decreasing inflammation and JNK activity ( P = 0.009). On day 8, OM further reduced IL-6 ( P = 0.002) and p38 MAPK ( P = 0.005) while increasing TGF-β1 ( P = 0.008) and PDGF ( P = 0.001), promoting proliferation. By day 14, increased ERK ( P = 0.008) and p38 MAPK ( P = 0.002) activity facilitated tissue repair. Wounds treated with 0.2% OM showed better outcomes than 1%, with more organized collagen (mean score 3.0 vs 2.3, P = 0.021), improved angiogenesis (3.4 vs 2.5, P = 0.038), and higher wound closure (87% vs 69%, P = 0.023). Conclusion: OM enhances wound healing by targeting each phase: reducing early inflammation, promoting mid-phase fibroblast proliferation, and supporting collagen organization in remodeling. These targeted effects suggest OM's therapeutic potential for wound repair.

5 December 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
MLMehdi Azizmohammad Looha
Mehdi Azizmohammad Looha
ASAli Saberi Shahrbabaki
Ali Saberi Shahrbabaki
MAMohammad Esmail Akbari
Mohammad Esmail Akbari
AMAzin Mohammadpoor
Azin Mohammadpoor
SKSoheila Khodakarim
Soheila Khodakarim
Background: Childhood cancer poses a growing global health burden. This study aimed to assess incidence patterns, temporal trends and five-year survival probabilities of childhood cancers in Iran using national cancer registry data from 2005 to 2014. Methods: A retrospective analysis was conducted using data from the Iran National Cancer Registry. After quality control procedures, 20,624 validated cases of childhood cancer (ages 0–14 years) were included. Age-standardized incidence rates (ASIRs) were calculated per million person-years using the new World Health Organization standard population. Trends over time were examined, and five-year observed survival probabilities were estimated for major diagnostic categories according to the International Classification of Childhood Cancer, Third Edition. Results: The overall ASIR for childhood cancers in Iran was 116.2 per million person-years, higher in males (128.1) than in females (103.6). The most common cancer groups were leukemia (ASIR: 31.7), lymphomas (ASIR: 13.2), and central nervous system neoplasms (ASIR: 12.6). Lymphoid leukemia was the most frequent subtype (ASIR: 26.6 in males, 20.0 in females). Joinpoint analysis indicated a modest but significant increase in overall ASIRs in both sexes (average annual percent change ≈ 3.5%), driven mainly by central nervous system and hepatic tumors, while retinoblastoma and Hodgkin lymphoma declined. The overall five-year survival was 81.0%, improving from 70.2% in 2005–2009 to 81.4% in 2010–2014. The highest survival was observed in lymphomas (97.1%), followed by retinoblastoma (96.9%), and soft tissue sarcomas (90.7%), while the lowest was found in neuroblastoma (39.1%). Children aged 0–4 years had the lowest survival (79.6%), compared with 82.9% and 82.0% in those aged 5–9 and 10–14 years, respectively. Conclusions: This nationwide study presents a comprehensive analysis of childhood cancer incidence and survival in Iran. The findings indicate a gradual increase in incidence, particularly among boys and younger children. Survival appears to have improved over time, though variations by age and cancer type warrant cautious interpretation due to differences in follow-up and case mix. These findings highlight progress in pediatric oncology in Iran and underscore the importance of strengthening cancer registration, diagnostic capacity, and equitable access to specialized care to further improve outcomes for children with cancer.

29 April 2026 in Health Science Reports
Verified
Journal Article
Open access
MLMehdi Azizmohammad Looha
Mehdi Azizmohammad Looha
ASAli Saberi Shahrbabaki
Ali Saberi Shahrbabaki
FMFatemeh Masaebi
Fatemeh Masaebi
MZMahmoud Zamani
Mahmoud Zamani
FZFarid Zayeri
Farid Zayeri
Background and Aims: Meningitis remains a global health challenge, characterized by substantial regional and etiologic disparities. This study aimed to analyze recent trends, forecast future burden, and examine the influence of development status on meningitis outcomes. Methods: We used Global Burden of Disease 2023 data to assess trends in age‐standardized incidence rate (ASIR), age‐standardized disability‐adjusted life‐year (DALY) rate (ASDR), and age‐standardized mortality rate (ASMR) for meningitis from 1990 to 2023 across regions and major etiologies. Temporal trends were assessed using joinpoint regression. Future projections through 2040 were generated using a hybrid time‐series model. Development‐related disparities were explored using multilevel regression based on the Human Development Index (HDI), and spatial clustering was analyzed. Results: From 1990 to 2023, global meningitis burden declined markedly, with ASIR, ASDR, and ASMR decreasing by roughly half. Despite these improvements, Sub‐Saharan Africa remained the most affected region in 2023, showing the highest ASIR, ASDR, and ASMR and the smallest proportional declines. Etiology‐specific analyses demonstrated substantial heterogeneity. Among bacterial causes, Streptococcus pneumoniae and Neisseria meningitidis remain the leading global contributors, while Haemophilus influenzae showed the steepest long‐term reductions. Viral meningitis was primarily driven by non‐polio enteroviruses, whereas Candida spp. represented the main fungal contributor. HDI‐based analyses revealed that although all development groups experienced declining trends, countries with higher HDI had consistently faster reductions across all three measures. Spatial clustering identified persistent high‐burden hotspots across the African meningitis belt. Projections to 2040 indicated continued global declines across all major etiologies, with S. pneumoniae expected to remain the predominant contributor and N. meningitidis showing the largest relative reductions. Conclusion: Despite substantial global declines, meningitis remains unevenly distributed, especially in Sub‐Saharan Africa, where incidence, DALY burden, and mortality remain highest. Projections show continued improvement, although Streptococcus pneumoniae is expected to remain the leading cause.